Achilles Therapeutics PLC (ACHL)
1.06
-0.01
(-0.93%)
USD |
NASDAQ |
Nov 22, 13:53
Achilles Therapeutics Shareholders Equity (Quarterly): 103.14M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 103.14M |
June 30, 2024 | 115.48M |
March 31, 2024 | 130.35M |
December 31, 2023 | 142.37M |
September 30, 2023 | 153.48M |
June 30, 2023 | 173.84M |
March 31, 2023 | 185.17M |
December 31, 2022 | 197.04M |
Date | Value |
---|---|
September 30, 2022 | 202.62M |
June 30, 2022 | 231.59M |
March 31, 2022 | 266.46M |
December 31, 2021 | 289.53M |
September 30, 2021 | 305.11M |
June 30, 2021 | 323.97M |
March 31, 2021 | 179.05M |
December 31, 2020 | 189.37M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
103.14M
Minimum
Sep 2024
323.97M
Maximum
Jun 2021
199.29M
Average
187.27M
Median
Shareholders Equity (Quarterly) Benchmarks
Autolus Therapeutics PLC | 476.96M |
Biodexa Pharmaceuticals PLC | 11.04M |
Centessa Pharmaceuticals PLC | 499.14M |
Adaptimmune Therapeutics PLC | 79.99M |
Verona Pharma PLC | 130.49M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 122.68M |
Total Liabilities (Quarterly) | 19.54M |